{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["[225Ac]Ac-AKY-1189"]],"indication":"previously treated locally advanced or metastatic solid tumors","name":"NECTINIUM-2","nct_id":"NCT07020117","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nectinium-2-nct07020117. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"[225Ac]Ac-AKY-1189","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2032-06","type":"ESTIMATED"},"conditions":["Urothelial Carcinoma Bladder","Triple Negative Breast Cancer (TNBC)","Hormone Receptor Positive Breast Adenocarcinoma","Non Small Cell Lung Cancer","Cervical Adenocarcinoma","Colorectal Adenocarcinoma","Head and Neck Cancer"],"enrollment":{"count":150,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"[225Ac]Ac-AKY-1189 (therapeutic)","otherNames":[],"type":"DRUG"},{"name":"[64Cu]Cu-AKY-1189 (imaging)","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-17","lead_sponsor":"Aktis Oncology, Inc.","official_title":"NECTINIUM-2: A Phase 1b, 2 Part, Multicenter, Single Arm, Open Label Study to Evaluate the Safety and Efficacy of a Nectin-4 Radiopharmaceutical ([225Ac]Ac-AKY-1189) in Patients With Previously Treated Locally Advanced or Metastatic Solid Tumors","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Part 1: Number of Patients with Dose-Limiting Toxicities","timeFrame":"From enrollment to the end of Cycle 1 (each cycle is 28 days)"},{"measure":"Part 1: Occurence of Adverse Events by Severity","timeFrame":"Up to the End of Treatment (30 days after the last dose)"},{"measure":"Part 2: Objective Response Rate (ORR)","timeFrame":"Up to 30 days following last administration"}],"references":[],"start_date":{"date":"2025-08-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors","url":"https://clinicaltrials.gov/study/NCT07020117"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nectinium-2-nct07020117"}